医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Chemical Succeeded Part of the Cefixime Business from Astellas Pharma

2019年06月05日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc. (Head Office: Chuo-Ku, Tokyo; President & CEO: Kenji Yasukawa, Ph.D.; hereinafter “Astellas Pharma”).

Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.

Cefixime developed by Astellas Pharma is a third-generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria and it is extensively prescribed worldwide.

In addition to the main business field of chemicals, Otsuka Chemical will continue strengthening the manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business and CMO business by taking advantage of key technologies cultivated in the field of organic and inorganic chemicals.

 

Company Profile

 

Otsuka Chemical Co., Ltd.
Established   :   August 29, 1950
Capital : 5 billion yen
President : Takeharu Harashima, President and Representative Director
Head Office : 3-2-27, Ote-Dori, Chuo-Ku, Osaka, 540-0021 Japan
Employees : 1,857 (consolidated; as of December 31, 2018)
Business Description

:

 

Manufacturing and sales of chemical products

 

Astellas Pharma Inc.

Established   :   April 1923
Capital : 103 billion yen
President : Kenji Yasukawa, President and CEO
Head Office : 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan
Employees : 16,243 (consolidated; as of March 31, 2019)

Business Description

:

  Research and development, manufacturing, and sales of pharmaceuticals
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006187/en/

CONTACT

Hidetosihi Hironishi
Otsuka Chemical Co., Ltd.
General Affairs
Occ.Release@otsuka.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2019年台湾医疗科技展展商简介
  • Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover
  • Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies
  • LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
  • AJC Organized the ASEAN Services Trade Forum in Tokyo to Discuss the Emerging Demands for Health and Social Services in ASEAN and Its Investment Opportunities